Retatrutide for PCOS is not a proven treatment. Retatrutide isn't FDA-approved for any condition, and we found no published trial testing its effects on PCOS symptoms. Its obesity trials explain the buzz, but they don't establish effects on periods, testosterone, or fertility. Legitimate access is limited to clinical trials or a narrow doctor-requested program.
The table below shows what was measured and what wasn't, row by row. After it comes the catch most pages skip: ovulation can return after years of irregular cycles. With no pregnancy-safety data for retatrutide, that matters.
RX Index Decision Verdict: Don't plan your PCOS care around retatrutide yet, and don't buy it online. Pick your main goal, then treat that goal with what's proven today.
- Best for: adults with PCOS and higher weight who want to compare approved options now instead of waiting.
- Not ideal for: anyone hoping for a retatrutide prescription, a compounded version, or a fertility boost.
- The factor that matters most: whether you could get pregnant in the next year. That changes which treatment makes sense, and when.
Retatrutide for PCOS: what has been measured, and what hasn't?
Retatrutide has caused large weight loss in adults with obesity. But no published PCOS-specific retatrutide study has established what it does to periods, ovulation, testosterone, or fertility. An obesity trial result can't be used to predict those outcomes.
PCOS stands for polycystic ovary syndrome. It's a common hormone condition, and the 2023 international guideline estimates that it affects 10% to 13% of women worldwide under widely used diagnostic criteria (2023 PCOS guideline). Retatrutide is investigational, which means it's still being studied and isn't approved for regular prescriptions.
Here's what is known, outcome by outcome, as of October 26, 2026.
| What you care about | Studied as a PCOS outcome? | What retatrutide research did show | What that does NOT prove | Source |
|---|---|---|---|---|
| Weight | No | TRIUMPH-1: 2,339 adults with obesity or overweight, no diabetes. At 80 weeks, the 12 mg group lost 25.0% of body weight on average vs. 3.9% on placebo | That you'd lose 25%, or that losing weight would fix your other PCOS symptoms | Lilly, May 21, 2026 |
| Blood sugar | No | Separate trials in adults with type 2 diabetes reported lower A1C (TRANSCEND-T2D-1, TRIUMPH-2) | That it treats the insulin problems in PCOS | Lilly FAQ, Sept 2026 |
| Insulin resistance | No | No PCOS insulin measures published | Any "% better insulin resistance in PCOS" figure you see online | 2023 PCOS guideline |
| Testosterone, acne, facial hair | No | No PCOS-specific results reported | Lower testosterone, clearer skin, or less hair growth | — |
| Periods and ovulation | No | No PCOS-specific results reported | Regular cycles or ovulation coming back | — |
| Getting pregnant | No | No PCOS-specific results reported | Better chances of pregnancy or a healthy birth | 2023 PCOS guideline, 5.9.1 |
| Safety in pregnancy | No | No published human pregnancy data found; no approved label | That it's safe around conception or pregnancy | Lilly FAQ |
| Birth control pills | No | No published interaction study found | That your pill works normally while on it | — |
| Side effects | No (not in PCOS) | Stomach and gut side effects were the most common in TRIUMPH-1 (see the trials section below) | That it's safe for you, for teens, or with other conditions | Lilly, May 21, 2026 |
| Getting it | — | Not approved. No retail price. Documented U.S. access paths are Lilly trials and a narrowly restricted doctor-requested expanded-access program | A routine prescription, telehealth order, retail coverage, or a lawful compounded version | FDA, current as of Oct 1, 2026 |
"Not established for PCOS" doesn't mean "doesn't work." It means there is no published PCOS-specific result you can count on. Someone with PCOS could have joined a broad obesity study without those outcomes being reported separately. A plausible idea is a reason to run a study, not a proven result.
You may also see PCOS called PMOS (polyendocrine metabolic ovarian syndrome). The American Society for Reproductive Medicine endorsed the new name on May 27, 2026 (ASRM). We use PCOS here because it's still the name most people know.
Why you'll see both 25% and 28.3%
Both numbers come from the same trial, TRIUMPH-1, 12 mg group, 80 weeks, adults with obesity. They answer different math questions. Neither is a PCOS result.
| Number | What it counts | Who it describes |
|---|---|---|
| 25.0% | Treatment-regimen analysis: estimates the average result regardless of stopping study treatment or starting other weight treatment | Adults with obesity or overweight, no diabetes |
| 28.3% | Efficacy analysis: estimates what the result would have been if everyone stayed on the assigned drug, allowing dose changes and interruptions | Same adults |
Think of it like a class grade. One number reflects what happened even when students missed lessons or switched courses. The other estimates how the class would have done if everyone stayed in the course. Both are real analyses, but neither predicts a result for someone with PCOS (Lilly).
Can you get retatrutide for PCOS?
No, not through a regular prescription. Retatrutide isn't approved, so no doctor, telehealth company, or pharmacy can fill an ordinary prescription for PCOS or anything else. Lilly says there is no public-use product. The documented special paths are its clinical trials and a narrowly restricted physician-requested expanded-access program (Lilly FAQ; Lilly expanded access).
Here's how each route actually works:
| Route | Real for PCOS? | What to know |
|---|---|---|
| Regular prescription or telehealth | No | Not approved. "Off-label" only applies to approved drugs, so it doesn't apply here |
| Clinical trial | Only if you fit a study | Having PCOS doesn't make you eligible. No trial we found listed PCOS as the condition being studied. Some studies give placebo (a look-alike with no active study drug) |
| Expanded access | Rare | Adults 18+ need BMI 35+ despite taking and tolerating the highest available chronic weight-management dose, two serious or life-threatening obesity-related complications under treatment, no accessible comparable trial, and a discussion of all standard options including surgery. Their treating doctor makes the request; Lilly and regulators review it. Meeting the rules does not guarantee access |
| Compounding pharmacy | No | The FDA says retatrutide cannot be used in compounding under federal law |
| "Research peptide" websites | No | The FDA has warned sellers that label these products "for research purposes" while selling them for people to inject |
If you want to check research options, start with the official lists, not a seller. You can search retatrutide studies on ClinicalTrials.gov or Lilly's trial finder. For the narrow doctor-requested route, see the official expanded-access record and our guide to who qualifies for retatrutide early access.
When could it be approved? No one knows yet. Lilly's last published filing plan is to submit a U.S. Biologics License Application in the first quarter of 2027. A plan to apply is not an approval, a price, or a pharmacy launch (Lilly, August 5, 2026). Our retatrutide availability guide tracks the timeline.
If you have PCOS, what can you do now?
The right next step depends on what you most want to fix: weight, blood sugar, periods, unwanted hair, or getting pregnant. The 2023 international PCOS guideline handles each of those with different tools (2023 PCOS guideline). A newer drug isn't automatically the right answer for every symptom.
Find your main goal in the left column.
| Your main goal | What the evidence supports now | A good next step |
|---|---|---|
| Managing higher weight | The guideline says GLP-1 medicines like liraglutide and semaglutide could be considered, along with lifestyle care, for adults with PCOS and higher weight, following general weight-loss rules | Ask a clinician whether you meet an approved medicine's weight criteria, then compare your options |
| Blood sugar or insulin worries | Metformin should be considered for adults with PCOS and a BMI of 25 or higher for metabolic results, including insulin resistance | Review your labs and past treatments with the clinician who manages your PCOS |
| Irregular periods, acne, facial hair | Combined birth control pills could be recommended for unwanted hair and irregular cycles, if they're safe for you | Talk with an OB-GYN or endocrinologist about symptom treatment |
| Trying to get pregnant | Letrozole is the guideline's first-choice medicine to help ovulation in suitable cases. Weight-loss drugs for fertility are recommended only in research settings | See an OB-GYN or fertility specialist first |
| PCOS without higher weight | Weight-loss drugs may not fit your goals or eligibility. The guideline also allows a discussion of metformin below BMI 25, but the evidence is more limited | Ask for treatment aimed at your cycles, hormones, and metabolic health |
| Thinking about a "research peptide" | The FDA says retatrutide can't be compounded and warns against these products | Don't buy it. Talk with a licensed clinician instead |
That fertility row surprises a lot of people. Even for approved GLP-1 medicines, the guideline doesn't recommend weight-loss drugs as a fertility treatment outside research (guideline 5.9.1). It's also worth knowing that the guideline describes drug treatment for PCOS itself as generally off-label. An approved weight drug may be prescribed on-label for weight management when someone meets that product's criteria, not because PCOS is its approved use (what FDA-approved and off-label mean).
Three quick questions can sort you out. You don't have to tell anyone the answers.
- Is your main goal weight, cycles and hormones, blood sugar, or pregnancy?
- Could you get pregnant in the next year?
- Do you have a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? (Those are common adult thresholds for weight-management medicines, not a guarantee of eligibility.)
If you're an adult focused on weight and not planning a pregnancy soon, you don't have to wait for retatrutide. Approved options with some PCOS research behind them exist now. Our best GLP-1 for PCOS guide compares them, and Mounjaro vs. Wegovy for PCOS helps if you're down to two.
The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and its formulary (your plan's medicine list), whether you'd use an FDA-approved or a compounded medicine, a shot or a pill, and your budget. Compounded medicines are not FDA-approved, and retatrutide cannot legally be compounded in the United States. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. It asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It won't prescribe retatrutide or confirm your plan's coverage.
If you're pregnant, trying to conceive, under 18, or have type 1 diabetes or a history of an eating disorder, skip the tool for now. Start with the clinician who knows your history. The PCOS guideline specifically says eating disorders should be considered in PCOS at any weight (guideline 2.5.1).
The PCOS catch: ovulation, pregnancy, and birth control
With PCOS, ovulation can be unpredictable. It may return as weight or treatment changes, so years of irregular periods are not reliable birth control. The PCOS guideline says people who could become pregnant while taking a GLP-1 medicine should use effective contraception because pregnancy safety data are lacking. Retatrutide has no approved label or established pregnancy-safety guidance.
Here's why this matters when your cycles have been unpredictable.
Your old "I can't get pregnant easily" may stop being true. The PCOS guideline warns that fertility can return rapidly after bariatric surgery and calls for birth-control counseling ahead of time. That is a finding about surgery, not proof that retatrutide restores ovulation (guideline 4.9.4).
Zepbound has a birth-control-pill warning. Retatrutide has no published interaction study. Zepbound (tirzepatide) can reduce the effectiveness of oral hormonal contraceptives because it delays stomach emptying. Its label says to switch to a non-oral method or add a barrier method such as condoms for 4 weeks after starting Zepbound and 4 weeks after each dose increase (Zepbound label, rev. 08/2026). Retatrutide acts on some of the same receptors, but that does not prove it has the same interaction. Ask a clinician about reliable contraception rather than borrowing another drug's instructions.
There's no FDA-approved pregnancy stopping schedule for retatrutide. Zepbound's label, for example, says to stop Zepbound when pregnancy is recognized. Retatrutide has no approved label or established preconception waiting period, so don't borrow another medicine's timeline.
Say you're 31. Your periods used to come every three or four months, so you assumed pregnancy was unlikely. After care for PCOS or a change in weight, they start coming more often. You might be ovulating again, though bleeding alone can't prove it. And if you take the combined birth control pill, a regular bleed during the pill break isn't proof of ovulation either (NHS).
If you could be pregnant while taking any weight-loss medicine, take a test and call your clinician. More on planning around these drugs: GLP-1s, pregnancy, and birth control.
What the retatrutide trials actually tested
Retatrutide is an experimental once-weekly shot that acts on three hormone receptors: GLP-1, GIP, and glucagon. Lilly calls it a "triple agonist" and says the nickname "GLP-3" is scientifically inaccurate (Lilly FAQ). Its trials studied weight, type 2 diabetes, and obesity-related problems, not PCOS.
| Study | Who was in it | What it measured | Main result | PCOS checked? |
|---|---|---|---|---|
| Phase 2 (NEJM, 2023) | 338 adults with obesity or overweight plus a weight-related condition | Weight at 48 weeks | 12 mg: 24.2% average loss vs. 2.1% placebo | No |
| TRIUMPH-1 (NEJM, Sept 2026) | 2,339 adults with obesity or overweight, no diabetes | Weight at 80 weeks | 12 mg: 25.0% vs. 3.9% placebo | No |
| TRANSCEND-T2D-1, TRIUMPH-2 (2026) | Adults with type 2 diabetes | Blood sugar (A1C) and weight | Lower A1C and weight vs. placebo | No |
| SYNERGY-Outcomes (ongoing) | Adults with high-risk fatty liver disease | Liver outcomes | Still running | No |
Sources: NEJM Phase 2 trial (2023); NEJM TRIUMPH-1 trial (2026); Lancet TRIUMPH-2 trial (2026); Lilly TRIUMPH-1 release; Lilly FAQ; our retatrutide trial tracker. A1C is a blood test that shows your average blood sugar over about 2 to 3 months.
Side effects were mostly in the gut. In TRIUMPH-1, people on 12 mg reported these more often than people on placebo (Lilly):
| Side effect | Retatrutide 12 mg | Placebo |
|---|---|---|
| Nausea | 42.4% | 14.8% |
| Diarrhea | 32.0% | 13.5% |
| Constipation | 26.1% | 10.9% |
| Vomiting | 25.3% | 4.8% |
The same trial also reported altered skin sensation (dysesthesia) in 12.5% of people on 12 mg, compared with 0.9% on placebo (Lilly). Those numbers come from a trial with medical monitoring. A vial bought online isn't the same product or the same setting. For the full picture, see what retatrutide trials report about side effects.
Could retatrutide still help insulin resistance or hormones in PCOS?
Maybe, and that's why it's worth studying. Insulin resistance (when your body doesn't respond well to insulin, so it makes more) is a key part of PCOS. But a reasonable idea isn't a result, and we found no published retatrutide study reporting insulin, testosterone, or cycle outcomes specifically in people with PCOS.
Be wary of any site that gives an exact number, like "lowers PCOS testosterone by X%" or "cuts insulin resistance by Y%." We found no published human retatrutide study reporting those PCOS-specific numbers. The PCOS guideline also says the insulin tests available in normal clinics aren't accurate enough for routine care (guideline 1.9.12). So a confident insulin percentage is a red flag.
Weight loss also isn't a cure. Many people with PCOS lose weight and still have irregular cycles or unwanted hair. That's not failure. It's a sign those symptoms need their own treatment, like the options in the goal table above.
If you're already using something sold as retatrutide
Products sold online as retatrutide are not approved medicine. The FDA says retatrutide can't be used in compounding and warns that "research use" products are of unknown quality (FDA). Lilly says anything sold to consumers outside its trials is illegal, with no way to verify safety, purity, or dose (Lilly FAQ).
No judgment here. Three things matter most:
- Tell a clinician exactly what you used. Bring the vial, label, and order page. A label can be wrong. Australia's drug regulator tested a product sold as retatrutide and found a different drug, semaglutide, instead (TGA).
- If pregnancy is possible, take a test and use reliable birth control. See the catch section above.
- Get care fast for serious symptoms. For severe belly pain, yellow skin or eyes, or trouble breathing, get urgent care or call 911. For questions about an unknown product, call Poison Control at 1-800-222-1222.
You can report problems to the FDA's MedWatch program. More on why there's no legal compounded version: compounded retatrutide.
What we actually verified
Checked October 26, 2026:
- Lilly's retatrutide FAQ (updated September 2026), for approval status, legal access, and its list of conditions studied
- The FDA's statement on unapproved GLP-1 drugs (content current as of October 1, 2026), for compounding and "research use" warnings
- The full 2023 international PCOS guideline recommendations hosted by ASRM, sections 1.9, 2.5, 4.1–4.5, 4.9, 5.3, and 5.9
- ASRM's May 27, 2026 announcement of the PMOS name
- Lilly's May 21, 2026 TRIUMPH-1 release, for trial size, results, and side effects
- The Zepbound prescribing information (revised 08/2026), for birth control and pregnancy wording
- The official retatrutide expanded-access registry record (last updated August 6, 2026; checked October 26, 2026), plus the access routes on our retatrutide availability page
What we didn't do: contact Lilly, enroll anyone, test any product, or review anyone's medical records. No retatrutide product was bought or used.
What we couldn't confirm: any PCOS data Lilly may hold but hasn't published, an approval date, or a price. Not finding a published PCOS study isn't proof that retatrutide has no effect in PCOS. This page has not been medically reviewed.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Read our methodology.
Retatrutide and PCOS: questions people ask
Can retatrutide help with PCOS?
It might, but we found no published trial directly testing retatrutide for PCOS symptoms. It causes large weight loss in studied adults with obesity or overweight, and some people with PCOS also have higher weight. Until a study measures cycles, testosterone, and fertility in PCOS, it's a hope, not a proven treatment.
Is retatrutide being studied for PCOS?
Not as a PCOS-focused study that we could verify. Lilly lists its retatrutide studies in obesity, type 2 diabetes, knee osteoarthritis pain, sleep apnea, low back pain, heart and kidney outcomes, and fatty liver, but not PCOS (Lilly FAQ). We'll update this page if that changes.
Is retatrutide FDA-approved for PCOS?
No. As of October 26, 2026, retatrutide isn't FDA-approved for PCOS or any other condition. No GLP-1 medicine is approved specifically to treat PCOS either.
Will retatrutide lower my testosterone or bring my period back?
That hasn't been studied in PCOS. Hormone and cycle changes have to be measured directly, even when weight results look strong. A gynecologist or endocrinologist can treat those symptoms now with better-studied options, like birth control pills or metformin.
Will retatrutide help me get pregnant?
There's no evidence it does, and its safety in pregnancy is unknown. The PCOS guideline recommends weight-loss drugs for fertility only in research settings, and names letrozole as the first-choice medicine to help ovulation. If pregnancy is your goal, start with an OB-GYN or fertility specialist.
Will retatrutide affect my birth control?
No published retatrutide–oral-contraceptive interaction study was found. Zepbound (tirzepatide), a different drug, can reduce birth-control-pill effectiveness; its label calls for a non-oral method or added barrier protection for 4 weeks after starting and after every dose increase. That warning has not been established for retatrutide, so ask your clinician rather than assuming the same rules apply.
Can I take metformin with retatrutide?
Retatrutide was studied with background metformin in adults with type 2 diabetes, but not for PCOS. It isn't available by ordinary prescription; the special paths are trials and rare physician-requested expanded access. Don't stop or change a medicine because of retatrutide headlines. Ask your clinician whether metformin, or metformin plus an approved option, fits your situation (TRIUMPH-2 trial).
Is retatrutide better than tirzepatide for PCOS?
No study has compared them in PCOS. Comparing weight numbers from separate obesity trials can't tell you how either one affects PCOS hormones or fertility. See retatrutide vs. tirzepatide for what the trials do show.
Can my doctor prescribe or compound retatrutide?
No. A regular prescription isn't possible because the drug isn't approved. The FDA says retatrutide can't be used in compounding under federal law. Trials and Lilly's narrow expanded-access program are separate, special routes.
Are "research peptide" retatrutide products safe?
The FDA warns people not to buy unapproved GLP-1 products sold "for research purposes" for personal use, including retatrutide. Their contents, strength, and handling are unknown. If you've already used one, tell a licensed clinician what you took.
What if I have PCOS but I'm not overweight?
PCOS can cause cycle, hormone, and blood sugar problems at any weight. A weight-loss drug may not fit your goals, and retatrutide has no proven PCOS use. Ask for treatment aimed at the symptoms and lab results you actually have.
Does insurance cover a GLP-1 because I have PCOS?
PCOS alone doesn't guarantee GLP-1 coverage. Coverage depends on the exact drug, an approved indication you meet, and your specific plan's rules, which may include prior authorization (a permission slip from your insurer). See how GLP-1 insurance coverage works and check your own plan's formulary.
Sources
Checked October 26, 2026, unless noted. Dates in parentheses belong to the source.
- Eli Lilly — What to know about retatrutide (updated September 2026)
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026)
- ASRM — Recommendations from the 2023 International Evidence-based Guideline for PCOS/PMOS (2023)
- ASRM — PCOS is now PMOS: understanding the name change (May 27, 2026)
- Eli Lilly — Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1) (May 21, 2026)
- Eli Lilly — Zepbound prescribing information (revised 08/2026)
- ClinicalTrials.gov — Retatrutide expanded access, NCT07629401 (registry updated August 6, 2026; rechecked October 26, 2026) and retatrutide study search (indexed search checked October 26, 2026)
- Therapeutic Goods Administration — Tested product sold as retatrutide (September 14, 2026; rechecked October 26, 2026)
- FDA — MedWatch reporting
- NEJM — Phase 2 retatrutide obesity trial (June 26, 2023)
- NEJM — TRIUMPH-1 Phase 3 obesity trial (September 29, 2026)
- Lancet — TRIUMPH-2 Phase 3 type 2 diabetes and obesity trial (online September 29, 2026; issue October 10, 2026)
- Eli Lilly — Expanded access policy and retatrutide filing plan (August 5, 2026)
- NHS — How to take the combined birth control pill (withdrawal bleeding)
- ClinicalTrials.gov — Retatrutide expanded access researcher record (registry update posted August 6, 2026; rechecked October 26, 2026)